NEW YORK (GenomeWeb) – Veracyte and Loxo Oncology said today that they have forged a research partnership to help develop targeted cancer drugs.

Under the terms of the agreement Veracyte will use its RNA sequencing-based assay, Afirma Xpression Atlas, to assess TRK fusions and RET alterations in thyroid cancers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
31
Sponsored by
Roche

This webinar highlights the use of single-cell genomics to identify distinct cell types and states associated with enhanced immunity.

Feb
14
Sponsored by
Oxford Nanopore Technologies

This webinar will describe a project that applied Oxford Nanopore long-read RNA-seq to explore the transcriptional landscape of a damaging agricultural pest.

Feb
19
Sponsored by
Pillar Biosciences

This webinar will demonstrate how clinical laboratories can develop their own customized targeted next-generation sequencing (NGS)-based solid tumor panels.